Are novel serum biomarkers informative?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22391247.
- Also identified by DOI 10.1016/j.mcna.2012.01.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To justify use in routine coronary heart disease (CHD) risk assessment, a novel serum biomarker must be specifically associated with future CHD events and add information beyond techniques currently available. Current risk assessment techniques are probabilistic and imperfect; however, to date, no novel serum biomarker has improved substantially on the current population-based risk stratification approach. Although limited trial-based data are available to assess the utility of biomarkers, insights gained from biomarkers may enhance clinical decision making. Continued basic science and population-based research into CHD biomarkers may help to further the capacity for CHD risk assessment.
Medical subject headings
- Apolipoprotein B-100
- C-Reactive Protein
- Coronary Disease
- Lipoprotein(a)
- Models, Statistical
- Risk Assessment
- Troponin I